Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 71205-525

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 71205-525). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

71205-525-30 (Image 01)

This is the description of Duloxetine 20mg capsules with NDC 71205-525-30 by ProficientRx. Each delayed-release capsule contains 22.4mg of duloxetine hydrochloride, USP equivalent to 20mg duloxetine. The capsules are blue opaque cap and body, imprinted with "logo" and 2890 on both cap and body in black ink. These capsules are RX only and should be dispensed with the medication guide provided separately to each patient. The product is manufactured by Actavis Eizabeth LLC Eizabeth, NJ 07207 USA and packaged by Proficient Rx LP, Thousand Oaks, CA 91320. The GTIN is 0037120525309 and the expiry date is 00/0000 with Lot#00000.*

FDA Label Image

1 (Image 1)

FDA Label Image

Figure6 (Image 10)

FDA Label Image

Figure8 (Image 11)

This text displays a chart comparing the percentage of patients improved with either a placebo or duloxetine delayed-release 60/120 mg once daily. The chart also includes the percent improvement in pain from baseline.*

FDA Label Image

Figure9 (Image 12)

The text provides a graph representing the percentage of patients who reported improvements with Duloxetine Delayed-Release 60 mg once daily and a placebo. There is also a line chart representing the percent improvement in pain from the baseline. Therefore, the description would be: "The text shows a graph comparing the effectiveness of Duloxetine Delayed-Release 60 mg once daily and a placebo, and a line chart displaying the percentage of improvement in pain from baseline."*

FDA Label Image

Figure10 (Image 13)

The text provides data on the percentage of patients improved with placebo and Duloxetine Delayed-Release 60/120 mg Once Daily. It also gives information on the percent improvement in pain from the baseline.*

FDA Label Image

1 (Image 14)

FDA Label Image

1 (Image 2)

FDA Label Image

1 (Image 3)

FDA Label Image

1 (Image 4)

FDA Label Image

Figure1 (Image 5)

FDA Label Image

Figure2 (Image 6)

The text describes a graph showing the proportion of patients with relapse over time from randomization to relapse in days on a clinical trial of placebo versus duloxetine delayed-release capsules. The graph appears to use a Kaplan-Meier method for analysis.*

FDA Label Image

Figure3 (Image 7)

This text provides a heading titled "Percentage of Patients Improved" followed by a blank space and then another heading "Percent Improvement in Pain from Baseline". It does not contain any further information or context to determine what it refers to.*

FDA Label Image

Figure4 (Image 8)

FDA Label Image

Figure5 (Image 9)

The text shows a chart that displays the percentage of improvement in pain from baseline for three different medications - DUL 60 mg Twice Daily, DUL 60 mg Once Daily, and Placebo.*

FDA Label Image

Image2890

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.